Maydan Rothblum - Feb 29, 2024 Form 4 Insider Report for Glimpse Group, Inc. (VRAR)

Signature
/s/ Maydan Rothblum
Stock symbol
VRAR
Transactions as of
Feb 29, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 10:11 AM
Previous filing
Oct 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRAR Stock Option (Right to Purchase) Disposed to Issuer $0 -320K -100% $0.00* 0 Feb 29, 2024 Common Stock 320K Direct F1, F2
transaction VRAR Stock Option (Right to Purchase) Award $0 +306K $0.00 306K Mar 1, 2024 Common Stock 306K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the forfeiture of fully vested options to purchase an aggregate of 320,180 shares of common stock granted under the issuer's 2016 equity incentive plan, as amended (the "2016 Plan"), consisting of options to purchase (i) 25,008 shares of common stock and 8,328 shares of common stock granted on September 1, 2019 and September 1, 2020, respectively, with an exercise price of $4.00/share, (ii) 33,333 shares of common stock granted on January 1, 2021 with an exercise price of $4.50/share, (iii) 8 shares of common stock and 3 shares of common stock granted on September 1, 2020 and January 1, 2021, respectively, with exercise prices of $4.00/share and $4.50 /share, respectively, (iv) 2,333 shares of common stock and 1,167 shares of common stock granted on July 1, 2020 and August 1, 2020, with an exercise price of $4.50/share, and (v) 250,000 shares of common stock granted on June 20, 2017, with an exercise price of $2.50.
F2 The options in footnote (1) were to expire 10 years from their respective grant dates.
F3 Mr. Rothblum was granted options to purchase an aggregate of 306,145 shares of the issuer's common stock under the 2016 Plan on March 1, 2023, consisting of (i) options to purchase 18,715 shares of common stock, at an exercise price of $3.00 per share, which options vest on March 1, 2025, (ii) options to purchase 18,715 shares of common stock, at an exercise price of $2.50 per share, which options vest on March 1, 2026, (iii) options to purchase 18,715 shares of common stock, at an exercise price of $2.00 per share, which options vest on March 1, 2027, and (iv) options to purchase 250,000 shares of common stock, at an exercise price of $1.50 per share, which vest monthly over 45 months. All of the foregoing options, other than the option to purchase 250,000 shares of common stock, expire seven years from the grant date. The option to purchase 250,000 shares of common stock expires ten years from the grant date.